DDX17 and non-small cell lung carcinoma: In non-small cell lung cancer (NSCLC), DDX17 dissociates the complex formed by E-cadherin and β-catenin, promotes nuclear translocation of β-catenin and enhances its transcriptional activity, thereby activating the Wnt/β-catenin pathway and enhancing cellular resistance to gefitinib (16).